Posted by SJW on August 29, 2005, at 7:14:26
In reply to Re: New class of psych drug » KaraS, posted by linkadge on August 26, 2005, at 6:44:57
Some animal studies have shown that one action of the NMDA receptor antagonists(MK-801,PCP) is that of AMPA receptor potentiator, especially in the prefrontal cortex.
The NMDA antagonist(Dextromethorphan) was the main ingredient of a cocktail that has thus far been the only thing that actually corrected(100%) my treatment resistant(defiant) depression, anxiety, chronic fatigue and cognitive decline. But unfortunately there are many risks and side effects that forced me to halt further treatment with that class of drugs.
So, I will be the first in line when and if Ampakines pass the clinical trials and meet FDA approval.
As a side note; Cortex Pharmaceuticals was the first that I know of to discover/design "Ampakines" and Servier for what it's worth is a financial supporter of Cortex.